Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBIT (2016 - 2025)

Fate Therapeutics' EBIT history spans 14 years, with the latest figure at -$34.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 43.77% year-over-year to -$34.7 million; the TTM value through Dec 2025 reached -$147.7 million, up 29.76%, while the annual FY2025 figure was -$147.7 million, 29.76% up from the prior year.
  • EBIT reached -$34.7 million in Q4 2025 per FATE's latest filing, roughly flat from -$34.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$28.6 million in Q1 2023 to a low of -$86.4 million in Q3 2022.
  • Average EBIT over 5 years is -$53.7 million, with a median of -$51.2 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 107.74% in 2021, then skyrocketed 61.6% in 2023.
  • A 5-year view of EBIT shows it stood at -$69.4 million in 2021, then rose by 7.15% to -$64.4 million in 2022, then increased by 25.37% to -$48.1 million in 2023, then decreased by 28.44% to -$61.7 million in 2024, then soared by 43.77% to -$34.7 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's EBIT are -$34.7 million (Q4 2025), -$34.7 million (Q3 2025), and -$37.0 million (Q2 2025).